ArticleBMC cancer2021
Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Non-pharmacological interventions and quality of life in female survivors of hormone receptor-positive breast cancer receiving adjuvant endocrine therapy: A systematic review.Anales del sistema sanitario de Navarra · 2026Pooled it
- Combined Aerobic and Resistance Training Improves Body Composition, Alters Cardiometabolic Risk, and Ameliorates Cancer-Related Indicators in Breast Cancer Patients and Survivors with Overweight/Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of sports science & medicine · 2024Pooled it
- Long-Noncoding-RNA HOTAIR Upregulation is Associated with Poor Breast Cancer Outcome: A Systematic Review and Meta Analysis.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- Leveraging immune and clinicopathological profiles with machine learning to predict axillary lymph node metastasis in breast cancer patients.Breast cancer research : BCR · 2026Observational
- Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period.Journal of managed care & specialty pharmacy · 2026Article
- Robust Association of Breast Cancer Co-morbidity Using Subtype-specific Expressed Genes.Current drug targets · 2026Article
- Tumor biology and access to care and metastatic breast cancer outcomes.Breast cancer research and treatment · 2025Article
- Article
- Life's Essential 8 and Cardiovascular Disease in Breast Cancer Survivors.Current cardiology reports · 2025Review
- Characteristics, Outcomes, and Risk Factors in Primary and Secondary Angiosarcoma: A Retrospective Cohort Study.The breast journal · 2025Article
- Unraveling the anti-inflammatory effects of Mediterranean diet in patients with cancer remission.Frontiers in immunology · 2025Article
- Association of Triglycerides and HbA1c Levels with Stages of Invasive Ductal Breast Cancer: A Prospective Study.Journal of pharmacy & bioallied sciences · 2024Article
- Efficacy and safety of nanoparticle albumin‑bound paclitaxel compared with solvent‑based paclitaxel in adjuvant therapy for breast cancer: A retrospective study.Oncology letters · 2024Article
- Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma.bioRxiv : the preprint server for biology · 2024Article
- The dual role of autophagy in the regulation of cancer treatment.Amino acids · 2024Review
- The Impact of Chemotherapy on Cardiovascular Mortality across Breast Cancer Subtypes.Current oncology (Toronto, Ont.) · 2024Article
- Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study.Lipids in health and disease · 2024Article
- Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer.Cancers · 2023Article
- Seven preoperative factors have strong predictive value for postoperative pneumonia in patients undergoing thoracoscopic lung cancer surgery.Translational lung cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundObesity and other metabolic comorbidities affect over 10% of patients with breast cancer and are closely related with adverse outcomes. Although metabolic comorbidities among breast cancer patients in low- and middle-income countries are suggested to be lower, only a few studies are currently available. Effective management of metabolic comorbidities in cancer patients has been associated with better outcomes.
methodsNon-metastatic breast cancer patients (N = 1081) treated in our department (2014-2018) were monitored for the presence of high Body Mass Index (BMI), diabetes or glucose intolerance, dyslipidemia, and hypertension and the development of recurrent metastatic diseases during a median follow-up of 3.9 years.
resultsGlucose intolerance, hypertension, dyslipidemia, and BMI ≥ 27.7 kg/m
conclusionMetabolic comorbidities were frequently found in breast cancer patients and were associated with higher risks to develop recurrent metastatic disease, particularly in post-menopausal women. Subsequent larger studies are needed to better understand the association of metabolic comorbidities with patients' quality of life and prognosis, and to explore the potential combination of clinical intervention and lifestyle modification in breast cancer survivors to treat as well as reduce their impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.